Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

EVERSANA and OptimizeRx Partner to Deliver High Tech and High Touch Pharmaceutical Services

EVERSANA and OptimizeRx Corp. announced their partnership to modernize the patient experience and improve health outcomes by combining a real-time electronic health records (EHR) network with customized, wraparound patient support services.

Read More »

Novartis’ Sandoz strikes deal for biosimilar of Herceptin

Novartis AG’s Sandoz division struck a deal with Taiwan’s EirGenix Inc. to market a biosimilar version of Roche’s Herceptin that is in late-stage development to treat some cancer tumors.

Read More »

AbbVie’s Skyrizi drug to treat psoriasis wins U.S. approval

The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.

Read More »

Acting Commissioner Ned Sharpless Affirms Commitment to FDA’s Current Course

U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.

Read More »

The Brink of the Biosimilar Revolution

Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020 – if the price is right.

Read More »

EVERSANA unveils new global market access research solutions from Health Strategies Insights

EVERSANA, the leading independent provider of global services to the life science industry, introduced a new suite of global market access solutions from Health Strategies Insights to help biopharmaceutical manufacturers understand the latest global trends in access, payment, distribution and administration.

Read More »

Novartis generics boss quits amid conjecture over business’s future

Novartis’ generics chief stepped down after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.

Read More »

AbbVie’s Humira Remains Top-Selling Rx Drug for 2018

AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.

Read More »

FDA approves Pfizer’s biosimilar to Roche’s Herceptin

The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche AG’s blockbuster breast cancer treatment Herceptin.

Read More »

Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

Samsung Bioepis Co. Ltd. announced the company’s expansion in mainland China through a licensing agreement with C-Bridge Capital. The transaction covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12 – which reference Lucentis (ranibizumab) and Soliris (eculizumab) – as well as the biosimilar candidate SB3 that references Herceptin (trastuzumab).

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom